NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
Clinical Trials
31 trialsNCT01397877 2023-09-06
ENDOPIK
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT02340780 2023-08-22
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Phase 2 Completed
NCT02220855 2022-04-11
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Indiana University
Phase 2 Completed
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT01806649 2021-10-11
BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy
Prince of Songkla University
Phase 2 Terminated
NCT01695473 2021-01-13
Neoadjuvant BKM120 in High-risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01816594 2019-11-14
NeoPHOEBE
Novartis
Phase 2 Completed
NCT01737450 2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2 Completed
NCT01289041 2019-05-30
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
Novartis
Phase 2 Completed
NCT01339052 2019-03-19
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01487265 2019-03-06
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02303041 2019-01-29
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Stanford University
Phase 2 Terminated
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01833169 2018-10-19
SIGNATURE
Novartis
Phase 2 Completed
NCT01693614 2018-09-28
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Novartis
Phase 2 Completed
NCT01923168 2018-09-14
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Novartis
Phase 2 Completed
NCT01852292 2018-07-24
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Novartis
Phase 2 Terminated
NCT02404844 2018-04-20
PIKTAM
University Hospital, Essen
Phase 2 Completed
NCT02301364 2017-10-19
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01385293 2017-05-19
BKM120 in Metastatic Castration-resistant Prostate Cancer
Duke University
Phase 2 Terminated
NCT02452294 2017-05-03
BUMPER
University Hospital Tuebingen
Phase 2 Unknown
NCT01613677 2017-04-20
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
Novartis
Phase 2 Withdrawn
NCT01830504 2016-10-05
BKM120
Hospices Civils de Lyon
Phase 2 Unknown
NCT01297491 2016-03-11
BASALT-1
Novartis
Phase 2 Completed
NCT02035124 2016-02-11
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT01501604 2015-09-17
BKM120 in Cancers With PIK3CA Activating Mutations
Massachusetts General Hospital
Phase 2 Withdrawn
NCT01953445 2014-12-08
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT01550380 2014-07-29
BKM120
University of Utah
Phase 2 Withdrawn
NCT01527877 2012-10-08
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
Yonsei University
Phase 2 Unknown